
AbbVie’s TEPKINLY Wins EU Approval for Follicular Lymphoma
The European Commission has authorized the use of TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, marking the first time a chemotherapy-free, bispecific-based therapy has been approved for this condition in a second-line setting across Europe.




















